Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2023

- 06 June 2023 - 1 mins read

Aggregated presentation by day and by market

 

Name of issuer

 Identification code of issuer (Legal Entity Identifier)  

Day of transaction

  

Identification code of financial instrument

 Aggregated daily volume (in number of shares)  

Daily weighted average price of the purchased shares *

  

Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 01/06/2023 FR0010259150 284 111,21 AQEU
IPSEN 549300M6SGDPB4Z94P11 01/06/2023 FR0010259150 690 111,19 CEUX
IPSEN 549300M6SGDPB4Z94P11 01/06/2023 FR0010259150 24 111,26 TQEX
IPSEN 549300M6SGDPB4Z94P11 01/06/2023 FR0010259150 2 979 110,74 XPAR
IPSEN 549300M6SGDPB4Z94P11 02/06/2023 FR0010259150 712 110,99 AQEU
IPSEN 549300M6SGDPB4Z94P11 02/06/2023 FR0010259150 549 110,94 CEUX
IPSEN 549300M6SGDPB4Z94P11 02/06/2023 FR0010259150 458 111,01 TQEX
IPSEN 549300M6SGDPB4Z94P11 02/06/2023 FR0010259150 3 681 110,81 XPAR
* Two-digit rounding after the decimal   TOTAL 9 377 110,86  

Attachment

Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
20 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
16 June 2023 6 mins read

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
16 June 2023 4 mins read

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
13 June 2023 8 mins read

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
13 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023